SCHEMBL5228581

SCHEMBL5228581

CC(C)C(C#N)(CCCN1CCN(CCOc2cccc(C#N)c2)CC1)c1sccc1C#N

nearest known ligand 0.43

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
CACNA1B Q00975 3/20 0.43
HRH1 P35367 2/20 0.43
CCR3 P51677 1/20 0.43
HRH2 P25021 1/20 0.39
MEN1 O00255 3/20 0.38
KMT2A Q03164 2/20 0.38
KCNA5 P22460 2/20 0.38
TBXAS1 P24557 1/20 0.38
ACACB O00763 1/20 0.37
DRD2 P14416 2/20 0.37
DRD3 P35462 1/20 0.37
LMNA P02545 1/20 0.36
MAPK1 P28482 1/20 0.36
HTT P42858 1/20 0.36
SMN1; SMN2 Q16637 1/20 0.36
HTR1A P08908 1/20 0.36
HTR2A P28223 1/20 0.36
IKBKB O14920 1/20 0.36
HTR2C P28335 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14431861 0.90 CACNA1B (0.41) CACNA1BMEN1KMT2ADRD2LMNA
SCHEMBL5229426 0.87 CACNA1B (0.44) CACNA1BHRH1CCR3HRH2MEN1
SCHEMBL7496354 0.86 ALDH1A1 (0.47) CACNA1BHRH1MEN1KMT2AKCNA5
SCHEMBL5227355 0.85 CACNA1B (0.44) CACNA1BHRH1CCR3HRH2MEN1
SCHEMBL5753857 0.84 CACNA1B (0.54) CACNA1BHRH1CCR3HRH2MEN1
SCHEMBL5241063 0.84 CACNA1B (0.47) CACNA1BHRH1CCR3HRH2MEN1
SCHEMBL14431848 0.83 CACNA1B (0.46) CACNA1BHRH1CCR3HRH2MEN1
SCHEMBL14432344 0.83 CACNA1B (0.42) CACNA1BHRH1CCR3HRH2MEN1
SCHEMBL5230681 0.82 CACNA1B (0.43) CACNA1BHRH1CCR3HRH2MEN1
SCHEMBL5241908 0.82 CACNA1B (0.44) CACNA1BHRH1CCR3HRH2MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1254895-B1 NITROGENOUS CYCLIC COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME EISAI R&D MAN CO LTD (JP) 2007-05-23 EP claimed
US-6906072-B1 Piperazine compound and pharmaceutical composition containing the compound EISAI CO., LTD. (JP) 2005-06-14 US claimed
US-20040220193-A1 Nitrogen-containing cyclic compound and pharmaceutical composition containing the compound EISAI CO., LTD. 2004-11-04 US claimed
EP-1818326-A1 Nitrogen-containing heterocyclic compounds and pharmaceutical composition containing the compounds Eisai R&D Management Co., Ltd. (JP) 2007-08-15 EP disclosed
EP-1254895-B1 NITROGENOUS CYCLIC COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME EISAI R&D MAN CO LTD (JP) 2007-05-23 EP disclosed
EP-1254895-B1 NITROGENOUS CYCLIC COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME EISAI R&D MAN CO LTD (JP) 2007-05-23 EP disclosed
US-20040220193-A1 Nitrogen-containing cyclic compound and pharmaceutical composition containing the compound EISAI CO., LTD. 2004-11-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040220193-A1 Nitrogen-containing cyclic compound and pharmaceutical composition containing the compound CACNA1D, CACNA1B, CACNA1E CACNA1B 2/4885HRH1 63/4885CCR3 1951/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.